Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This research is studying the effect of Antibody-Drug Conjugate Sacituzumab Govitecan in
Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor
Talazoparib in Patients with Metastatic Triple-Negative Breast Cancer.